Pexelizumab

Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction[1][2].

Product Specifications

CAS Number

[219685-93-5]

Product Name Alternative

H5G1. 1-SC

UNSPSC

12352203

Target

Apoptosis; Complement System

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pexelizumab.html

Solubility

H2O

Smiles

[Pexelizumab]

References & Citations

[1]APEX AMI Investigators, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007 Jan 3;297 (1) :43-51.|[2]Thomas TC, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec;33 (17-18) :1389-401.